EUZ.XETRA

Eckert & Ziegler sits across two different markets, and the two halves of this question have different answers. Isotope Products, the industrial and imaging-source business, is essentially a fixed and mature pie: it generated €140.9 million of 2025 revenue and €28.3 million of adjusted EBIT, and Q1 2026 external revenue there actually fell 7% to €31.5 million. Medical is where the ceiling is genuinely moving, because oncology's shift toward radioligand therapy in lutetium-177 and actinium-225 is pulling more economic value into the isotope-processing, generator and CDMO layer the company already occupies. Medical produced €171.0 million of revenue and €51.1 million of adjusted EBIT in 2025 on a 49% gross margin, rising to 54% in Q1 2026.

The report cites two external signals that the addressable pool is expanding at an industry level, not just for this one company: Reuters reported that the European Commission cleared roughly €2 billion of Dutch state aid for medical-isotope reactor capacity because shortages are expected after 2030, and the Financial Times reported that Eli Lilly moved into nuclear isotopes specifically to secure actinium-225 access. Both point to real scarcity recognized by governments and big pharma. What is still missing is evidence the company is testing that higher ceiling itself: 2026 guidance implies only about 3% revenue growth. The report's own peer table underscores how much room exists between its current scale and the sector's most valuable outcomes: at about €903 million of market capitalization, Eckert & Ziegler is a fraction of Lantheus's $6.66 billion or Novartis's $305 billion, so scarcity of addressable market is not the near-term constraint. The honest read is a market being reconfigured and enlarged around radiopharma, with Eckert & Ziegler positioned inside the growing part of it, but not yet pushing against its own capacity limits.

Doubling 2025 revenue of €312.0 million to roughly €624 million within five years is not supported by anything disclosed in this report. 2026 guidance implies only about 3% revenue growth to roughly €320 million, and the report's own scenario table, which only reaches out to 2028, tops out at about €425 million in the optimistic case, about €385 million in the base case, and about €350 million in the conservative case. Even the optimistic 2028 figure is only around 36% above 2025 revenue over three years, well short of doubling. Doubling in five years would require a compound growth rate of roughly 15% a year, a pace the company has not guided to and the scenario framework does not model. The five-year record explains the skepticism: revenue grew from €180.4 million in 2021 to €312.0 million in 2025, a cumulative 73% gain, but EBIT actually dipped to €44.5 million and €45.5 million in 2022 and 2023 from €47.4 million in 2021 before recovering, so growth and profit quality have not moved together throughout the period.

What growth does exist is increasingly a mix story rather than a volume story. Management explicitly credits Medical's improvement to pharmaceutical radioisotopes, generator sales, licensing income and CDMO-related activity, a shift toward higher-value revenue inside the existing customer base rather than simply selling more units. Genuinely new business lines, actinium-225 scale-up, the Jintan/Qi Kang joint venture in China, Lu-177 supply agreements and lead-212 access through Thor Medical, are real but still early: actinium production only began in December 2024 and was scaled again in February 2026, and the Jintan site only opened in June 2026. If those ramp faster than guided, the 2028 numbers could migrate toward the optimistic case, but even that case falls well short of a double.

The current growth engine, Medical's generator sales, licensing income and CDMO work, is really still the first curve, since it only became the group's dominant profit source in the past two reporting years. The clearest candidate for what comes next is actinium-225: the Ac-225 facility near Prague, run with UJF, only began production in December 2024 and was scaled further in February 2026, so it is barely two years into a commercial ramp, and the company does not publicly disclose enough detail on Ac-225 capacity or volumes for outside investors to size its contribution yet. The Jintan site in China, operated through the Qi Kang joint venture with DC Pharma, opened as recently as June 2026, though the relationship was already contributing cash before that: a €9 million cash inflow from Qi Kang showed up in H1 2025.

Two smaller options sit further out. Lead-212 access through the Thor Medical agreement is an early-stage payload diversification beyond the existing lutetium and actinium base. Geographic expansion of existing products, such as the Japanese approval for GalliaPharm and the European approval for Theralugand, extends the reach of what the company already sells rather than creating a new engine. None of these lines is disclosed with capacity, contract duration or pricing detail, so today's second curve is best described as a set of real but unproven options rather than a demonstrated growth driver. The next real evidence point is the H1 2026 report due 2026-08-13, which should show whether actinium and Jintan volumes are becoming visible in the numbers.

Three moats show up clearly in the disclosures. The first is regulatory: the company holds permits for handling, storage and transport of radioisotopes and runs GMP-grade purification facilities at multiple sites, a capability a biotech cannot quickly replicate. The second is decades of process know-how built through a long history of acquisitions across isotopes, hot cells, sources and downstream manufacturing, giving it breadth that single-slice competitors lack. The third is customer stickiness: once a generator, isotope or manufacturing process is embedded in a client's regulatory dossier for clinical work, switching means redoing comparability and timing work, not just re-signing a contract, which is why named agreements with AtomVie, Bicycle Therapeutics, Actinium Pharmaceuticals and Thor Medical, plus the new Qi Kang site, matter more than their headline size suggests.

Over the next three to five years the moat looks set to widen downstream and narrow upstream at the same time. Downstream, more named multi-payload agreements and expanding GMP capacity should deepen the switching-cost advantage. Upstream, the report flags a real threat: the Financial Times reported Eli Lilly's move into nuclear isotopes to secure actinium-225 access, and Reuters reported roughly €2 billion of Dutch state aid clearing for new isotope-reactor capacity, both signs that raw isotope supply will draw more capital and competition as shortages loom after 2030. Because the company's edge sits mostly in processing, purification and logistics rather than in owning a single scarce reactor, it is more insulated from that upstream pressure than a pure isotope producer would be, though the insulation is partial rather than complete.

There is a demonstrated pattern of self-reinvention, not just an aspiration to have one. The company traces back to a GDR-era isotope research institute and grew for decades as a roll-up of hard-to-handle regulated assets, but it has also repeatedly cut parts of itself when the strategic fit weakened: it divested the HDR tumor-irradiation business in 2021 because it diluted capital-market clarity, and it spun off Pentixapharm in 2024, three years after taking majority control, once management concluded that public investors should not have to underwrite a development-stage drug story inside the same listed vehicle as the isotope-supply business. The 2021 annual report even used unusually candid language about a "miraculous glut of cash" from the radiopharma financing wave, naming the strategic shift explicitly. The Executive Board was also trimmed from three members to two for 2026.

On handling bad news, the clearest test is the February 2025 cyberattack, which disrupted digital processes and generator deliveries, with effects management said extended into subsequent periods before recovery in Q2 2025. The disruption was disclosed in reporting rather than concealed, and there is no record of an accounting scandal or qualified audit opinion; Forvis Mazars has issued unqualified opinions throughout. That is a real, if limited, stress test: one operational shock, openly reported and worked through, rather than a core-business disruption that forced a genuine reinvention. The leadership transition around the same period was handled with similar pragmatism: Frank Yeager's Executive Board term ended at the close of 2025, yet he continued running Isotope Products operationally, avoiding the abrupt capability loss that often follows a governance shake-up.

Founder alignment is substantial. Co-founder Dr. Andreas Eckert chairs the Supervisory Board and held 31.16% of share capital, directly and indirectly, at 2025 year-end; the company names him the ultimate controlling party because of his historical majority of votes at annual meetings. The operating team is also long-tenured rather than freshly hired: CEO Harald Hasselmann has been with the company since 2015 and on the Executive Board since 2017, and Gunnar Mann, a physics-background operator, joined the board in January 2025 after a long internal career.

The evidence on sacrificing near-term profit for the long run is directional but credible. The 2025 shareholder letter explicitly restricts acquisitions to special cases and keeps the company focused on isotopes rather than opportunistic diversification. Recent capital spending in Dresden-Rossendorf, Berlin-Buch, São Paulo and Wilmington is described as clearly expansionary, well above the roughly €8 million to €10 million a year needed for maintenance, and it is funded from a balance sheet that still grew net financial position to €115.2 million rather than from new debt. That is money committed to actinium and generator capacity years before it shows up as reported growth, while 2026 guidance stays modest at only about 3%, meaning management is not managing the business to flatter near-term optics. The one governance caveat worth naming is related-party texture: founder-connected leases and a consultancy arrangement for a former Executive Board member who moved to the Supervisory Board, which the company describes as arm's length but which still argues for a modest discount given how concentrated control is.

Customers embedded in Eckert & Ziegler's Medical workflows would miss it considerably. Once the company supplies a generator, isotope, or purification and manufacturing step for a client's clinical program, that relationship sits inside the client's regulatory dossier, and switching means redoing comparability and timing work, not simply placing an order elsewhere. The named agreements with AtomVie for lutetium-177, Bicycle Therapeutics, Actinium Pharmaceuticals for actinium-225, and Thor Medical for lead-212, along with the new Qi Kang joint venture in Jintan, all sit inside that kind of embedded relationship rather than being commodity purchases that could be resourced overnight. That embeddedness also spans a genuinely multi-site production network, Berlin-Buch, Braunschweig, Dresden-Rossendorf, Řež, Wilmington, Boston and São Paulo alongside the new Jintan site, so no single facility or customer failure would likely end the relationship base at once.

On sustainability, the growth model leans on regulatory compliance rather than regulatory arbitrage: the report describes regulation as an ingredient of the business model rather than an external obstacle, and the company's edge exists precisely because it holds the licenses, GMP capability and handling permits that keep casual entrants out. The genuine caveat is environmental cost, which is inherent to handling radioactive material rather than a sign of misconduct: the 2025 balance sheet carries €44.0 million of non-current site-restoration provisions and €34.7 million of disposal provisions, a permanent tail cost the company funds directly rather than pushing onto others. The February 2025 cyberattack, which disrupted generator deliveries before recovering in Q2 2025, is the clearer reminder here: operational and IT resilience is the real fragility to watch, not the ethics of how the company grows.

Unit economics are good but tied to mix rather than to scale by itself. Medical's gross margin reached 49% in 2025 and rose further to 54% in Q1 2026, well above Isotope Products' 40% to 45% range, which itself slipped to 40% in Q1 2026 as the segment's mix weakened. Group EBIT margin has moved with investment cycles rather than rising steadily with size: it compressed from 26% in 2021 to 18% in 2023 during heavy reinvestment and portfolio rework, then recovered to 24% in 2025 with adjusted EBIT margin at 25%. The report is explicit that operating leverage here comes from product mix and utilization of regulated capacity, not from simply spreading fixed costs over more volume, so getting bigger only helps if the incremental revenue is generator sales, license income or CDMO work rather than lower-margin Isotope Products volume.

The cash goes mostly into growth capacity first, with modest shareholder distributions second. Spending in Dresden-Rossendorf, Berlin-Buch, São Paulo and Wilmington is described as clearly expansionary and tied to new generator and actinium-225 capacity, well above the roughly €8 million to €10 million a year needed just for maintenance. Despite that, net financial position still grew from €41.6 million in 2023 to €115.2 million in 2025, so growth is being funded from operating cash and existing cash rather than debt, alongside a modest roughly 1.5% dividend yield. The one wrinkle is 2025 itself, when operating cash flow fell 30% year on year to €58.4 million despite stronger earnings, as receivables and inventories absorbed cash to support higher revenue; the five-year 2021-2025 average operating-cash-flow-to-net-income ratio was still a healthy roughly 1.5 times.

Reaching roughly €72 a share, five times today's €14.43, within ten years would require several conditions to hold at once: revenue growth running far above the guided roughly 3% for years, closer to double-digit compounding than the modest 2026 outlook; Medical's margin continuing to expand past the 54% already reached in Q1 2026 without leaning on lumpy license timing; actinium-225, lutetium-177, the Jintan/Qi Kang joint venture and CDMO services all scaling from early-stage agreements into disclosed, multi-year, high-volume contracts; and the market re-rating the multiple well beyond the report's own optimistic band of 17 to 22 times EV/adjusted EBIT, since the report's own framework already flags anything above €20.7 as clearly overvalued.

That combination is not what the report's own numbers support. A 5x return in ten years needs roughly 17.5% annualized, while the report's expected-return bands top out at about 11% to 13% in the optimistic case, with the base case at 6% to 8% and the conservative case at just 1% to 2%. The 2028 scenario table, which only runs three years out, reaches a fair value near €20.1 even optimistically, about 39% above today's price, nowhere close to 5x. What today's €14.43 actually implies, on the report's own valuation analysis, is that the market is pricing roughly the conservative-to-low-base zone: credit for a quality, net-cash-rich business, but not for a dramatic radiopharma breakout. A ten-year 5x outcome is not the scenario priced into the stock today. The current setup is built for steady compounding, not a moonshot.

The report frames the delay as a complexity and disclosure gap. Eckert & Ziegler spans too many buckets for a single clean multiple: the report states directly that there is no perfect listed comparable, since most listed peers cover only one slice (Telix closer to commercial radiopharma products, Lantheus to nuclear-imaging commercialization, BWXT to broader nuclear infrastructure, Novartis to global radioligand brands) while this company combines industrial isotopes, radiopharma infrastructure, CDMO services and legacy brachytherapy in one vehicle. Layered on top is a genuine information gap: the company does not disclose enough detail on Lu-177 and Ac-225 capacity, contract pricing or customer concentration for outside investors to underwrite an aggressive growth curve with confidence, so bulls and bears are genuinely arguing over unresolved facts rather than one side simply being wrong.

One part of the gap does look like undervaluing the business rather than misunderstanding it: some investors likely still price the company closer to its older, broader industrial-conglomerate identity. The Medical margin improvement already shows up directly in the 2025 and Q1 2026 income statement, a 49% gross margin rising to 54%, ahead of how the market still seems to label the company. The narrative pivot the report points to is an accumulation of proof points rather than one single event: another quarter where Medical grows without meaningful license revenue, confirming repeatability rather than a one-off; newly disclosed multi-year supply or CDMO agreements with real scope and geography; and regulatory milestones such as further GalliaPharm geography expansion or GMP actinium progress. The next concrete checkpoint is the H1 2026 report due 2026-08-13.